5 Oversold Healthcare Stocks to Buy

In this article, we will take a look at the 5 oversold healthcare stocks to buy. To read our analysis of the recent trends and market activity, you can go to the 10 Oversold Healthcare Stocks to Buy.

5. NovoCure Limited (NASDAQ:NVCR)

14-day RSI as of August 4: 19.97

Number of Hedge Fund Holders: 19

Root, Switzerland-based NovoCure Limited (NASDAQ:NVCR) is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields.

The portfolio of NovoCure Limited (NASDAQ:NVCR) includes products approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma, and pleural mesothelioma. Its clinical trials pipeline includes Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.

On July 27, NovoCure Limited (NASDAQ:NVCR) released its financial results for Q2 2023. It generated a revenue of $126 million and a net loss of $57 million. During the quarter, phase 3 LUNAR trial in non-small cell lung cancer met primary and key secondary survival endpoints, and the interim analysis for its phase 3 PANOVA-3 trial in pancreatic cancer concluded with recommendation to proceed to final analysis.